Related Experiment Videos
Risk factors in complications of aqueous myelography
Abstract:
The adverse reactions from aqueous myelography in 88 primates were reviewed to determine what factors increase the risk of complications. Seventy-four iocarmate (Dimeray) myelograms were obtained on 41 animals, and 90 metrizamide (Amipaque) myelograms were obtained on 47 animals. The risk of seizures and death from iocarmate myelography was higher than from metrizamide myelography. In animals that had previous myelograms or showed evidence of arachnoiditis, the risk of complications from aqueous myelography was higher. Additional precautions may be indicated if aqueous myelography is performed in patients with arachnoiditis.
Insights
Aqueous myelography risks, including seizures and death, were higher with iocarmate (Dimeray) than metrizamide (Amipaque). Pre-existing arachnoiditis or prior myelograms increased complication risks in primates.
Area of Science:
- Veterinary Neurology
- Radiology
- Toxicology
Background:
- Aqueous myelography is a diagnostic imaging technique used to visualize the spinal cord and surrounding structures.
- Iocarmate (Dimeray) and metrizamide (Amipaque) are commonly used contrast agents for myelography.
- Understanding the risk factors associated with adverse reactions is crucial for patient safety.
Purpose of the Study:
- To review adverse reactions in primates undergoing aqueous myelography.
- To identify factors that increase the risk of complications during myelography.
- To compare the safety profiles of iocarmate and metrizamide contrast agents.
Main Methods:
- Retrospective review of adverse reactions in 88 primates following aqueous myelography.
- Analysis of 74 iocarmate (Dimeray) myelograms in 41 animals.
- Analysis of 90 metrizamide (Amipaque) myelograms in 47 animals.
Main Results:
- Iocarmate (Dimeray) myelography was associated with a higher risk of seizures and death compared to metrizamide (Amipaque).
- Primates with a history of previous myelograms or evidence of arachnoiditis exhibited increased complication risks.
- Complication rates were elevated in animals with pre-existing arachnoiditis.
Conclusions:
- Metrizamide (Amipaque) appears to be a safer contrast agent than iocarmate (Dimeray) for aqueous myelography in primates.
- Patients with arachnoiditis or a history of myelography may require additional precautions.
- Further research may be warranted to elucidate specific risk mitigation strategies.